Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Jun
11
Today In Oncology
New Research Links Low Alcohol Consumption to Elevated Health Risks
Digital Tool May Improve Patient Engagement in Oncology Clinical Trials
GLP-1 RAs May Reduce Risk of Obesity-Related Cancers
Teclistamab in Previously Treated Multiple Myeloma
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo